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We present a cross-species chemogenomic screening platform using libraries of haploid deletion
mutants from two yeast species, Saccharomyces cerevisiae and Schizosaccharomyces pombe.W e
screenedasetofcompoundsofknownandunknownmodeofaction(MoA)andderivedquantitative
drug scores (or D-scores), identifying mutants that are either sensitive or resistant to particular
compounds. We found that compound–functional module relationships are more conserved than
individual compound–gene interactions between these two species. Furthermore, we observed that
combining data from both species allows for more accurate prediction of MoA. Finally, using this
platform, we identiﬁed a novel small molecule that acts as a DNA damaging agent and demonstrate
that its MoA is conserved in human cells.
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Introduction
Understanding a compound’s mode of action (MoA) is a
requirement for rational therapeutics and for the under-
standing of drug resistance. Historically, this important
endeavor has been primarily focused on case-by-case studies
of antibacterial resistance, but technological developments
have resulted in several genome-wide approaches to drug
target discovery. Examples of these include studies of gene
expression changes after treatment with a small molecule
(Hughes et al, 2000; Lamb et al, 2006), physical isolation of
a drug–target complex through afﬁnity chromatography
(Rix and Superti-Furga, 2009) and whole-genome sequencing
of drug-resistant strains (Andries et al, 2005). In silico ligand
docking provides a computational approach to identifying
potential binding partners based on available crystallography-
and NMR-derived protein structures (Kolb et al, 2009).
Chemogenomics, or chemical genetic interaction proﬁling as
a means for drug target identiﬁcation, has been an area of
active interest for more than a decade (Giaever, 2003; Wuster
and Babu, 2008; Hoon et al, 2008b). A chemogenomic screen
examines a drug’s mode of action (MoA) by measuring the
effect of a drug treatment on a collection of genetically distinct
strains, typically a set with modiﬁed gene expression varying
from multi-copy/overexpression to complete gene deletion.
The development of mutant libraries in several model
organisms, including Saccharomyces cerevisiae (Winzeler
et al, 1999; Giaever et al, 2002), Schizosaccharomyces pombe
(Kim et al, 2010; http://pombe.bioneer.co.kr/), Candida
albicans (Rodriguez-Suarez et al, 2007) and Escherichia coli
(Baba et al, 2006), has greatly accelerated chemogenomic
screening. Combining individual drug–mutant relationships
(i.e.,resistanceorsensitivity)intoaproﬁleprovidesagenome-
wide viewof a compound’s effect on the cell. Comparing these
drugﬁtnessproﬁlestogeneticinteractionproﬁlescomposedof
double mutantinteractionscanaid intheidentiﬁcation of drug
targets (Parsons et al, 2004; Hoon et al, 2008a; Ho et al, 2009).
Additionally,comparingdrugproﬁlesmakesitpossibletoinfer
the MoA of a drug of interest by the similarity of its
chemogenomic proﬁle to proﬁles of drugs with known MoA
(Hillenmeyer et al, 2008, 2010). Finally, ﬁtness proﬁle
comparison has been used to identify pharmacophores in
structurally related molecules (Giaever et al, 2004; Ericson
et al, 2008).
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screening platform, involving two yeast species, S. cerevisiae
and S. pombe, that we use to study the evolution of drug
mechanism of action. To aid in this analysis, we have used
genetic interaction data derived from double mutant analysis
in both species (Schuldiner et al, 2005; Collins et al, 2007;
Roguev et al, 2008; Wilmes et al, 2008; Fiedler et al, 2009) in
conjunction with the chemogenomic proﬁles. We ﬁnd that
compound–functional module relationships are signiﬁcantly
more conserved than individual compound–gene interactions,
suggesting that modularity is a key aspect of the conservation
of drug response. Finally, we identify one small molecule
predicted to be involved in inducing DNA damage and
demonstrate that its MoA is conserved in S. cerevisiae,
S. pombe and human cells.
Results
Screening of National Cancer Institute Diversity
and Mechanistic Sets in S. cerevisiae and
S. pombe
We screened the 2957-member National Cancer Institute
(NCI) Diversity and Mechanistic Sets (http://dtp.nci.nih.
gov/branches/dscb/repo_open.html) in both S. cerevisiae and
S. pombe, using a high-throughput halo assay that measures
inhibition of growth (Gassner et al, 2007; Woehrmann et al,
2010) and predicts EC50 values (see Materials and methods for
description) for each compound (Figure 1A). The NCI
Diversity Set is a collection of compounds selected for
structural diversity, and the Mechanistic Set contains com-
pounds that have been tested in the NCI human tumor 60 cell
line screen. A total of 270 compounds were found to be
bioactive in at least one species (Figure 1B), 132 of which had
an effect in both ﬁssion and budding yeasts (Supplementary
Table 1). We observed an overall B2:1 ratio between the
predicted EC50 values in S. cerevisiae versus S. pombe,
indicating that ﬁssion yeast may be globally more sensitive
to drugs (Figure 1C). For each compound, nine chemical
properties (ClogP, polar surface area (PSA), number of atoms,
molecular weight, number of hydrogen-bond donors and
acceptors, number of violations of Lipinski’s Rules, number of
rotatable bonds and molecular volume) were considered. We
found no obvious difference between the properties of small
molecules that were bioactive only in one species (see
Supplementary information). However, when we compared
the properties of compounds that were active in at least one
species to those of the inactive compounds, we observed that
the ClogP, the predicted octanol–water partition coefﬁcient,
was more than 80% higher among bioactive compounds
(Po5.54 10
 12) (see Supplementary information). Bioactive
compounds also tended to have a lower PSA, a higher
molecular weight, lower number of hydrogen bond acceptors,
alower numberof hydrogenbond donors anda higher volume
than the inactive compounds. Taken together, these data
indicate that compact molecules that are non-polar or have
intramolecular hydrogen bonding partners are the most
bioactive in both yeast species.
Next, we used a growth assay (Figure 2A) to screen 21
bioactive compounds against libraries of S. pombe and
S. cerevisiae deletion strains arrayed in agar plates (Table I).
Of these 21 compounds, 12 are well-characterized compounds
that were selected based on a wealth of previous information
for benchmarking purposes, whereas the remaining were
randomly selected from those found to be bioactive in both
species in the halo assay (Table I). Using a previously
described algorithm designed to quantitatively assign genetic
interactions based on colony size (Collins et al, 2006), we
generated drug scores (or D-scores) indicating the effects of
compounds on individual mutations, either negatively (e.g.,
sensitivity) or positively (e.g., resistance) (Figure 2B). In this
analysis, we assume a neutral model, in which the expected
growth of a treated mutant would be the product of the growth
rates of the untreated mutant and compound-treated wild-type
cells. Growth less than this represents sensitivity (Figure 2B),
and could arise when a drug negatively impacts on a
component of a pathway acting in parallel to a pathway that
has a component mutated (Figure 2C). Better than expected
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Figure 1 High-throughput yeast halo assay identiﬁed bioactive compounds and predicts EC50 values. (A) A total of 2957 compounds from the National Cancer
Institute’s Diversity Set were arrayed in 384-well plates (10mM, DMSO). These small molecules were pin transferred to agar plates seeded with yeast cells and then
incubatedat251C.Theplates werereadwithaplatereader toidentifyhalosofdeath,andtheEC50valueispredictedfromthevolumeofthedeathhalo.(B)Ofthe2957
compoundsscreened,wefound271tobeactiveinatleastoneorganism.Eighty-fourcompoundsareactiveonlyinS.cerevisiae,55areactiveonlyinS.pombeand132
are active in both species. (C)E C 50 values are predicted for each small molecule based on halo volume. On average, we observed that S. pombe is approximately
2  more sensitive to a small molecule than S. cerevisiae.
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2 Molecular Systems Biology 2010 & 2010 EMBO and Macmillan Publishers Limitedgrowth, or resistance, could arise from a situation where the
drug target (or another protein functioning in the same
pathway as the target) is deleted (Figures 2B and C). Another
scenariowhereresistancecouldemergewouldbeoneinwhich
a compound binds to an enzyme and causes the protein to
carryoutafunctionthatisharmfultocellviability.Inthiscase,
deletion of the protein target would relieve the detrimental
effect, resulting in resistance (Figure 2C). An example of this
latter case would be the binding of the DNA damaging agent
camptothecin to the DNA/topoisomerase complex and
inhibiting the dissociation of Top1, an event that triggers the
DNA damage response (DDR) pathway. These examples are
intended to represent possible interpretations of the chemo-
genomic data, but many other possibilities exist. Finally,
collectively, the D-scores can be treated as a phenotypic
signature and can be compared with genetic interaction
proﬁles, generated from double mutations, to help identify
potential drug targets, as a proﬁle derived from a drug and a
mutation of the target should, in principle, result in similar
proﬁles (Figure 2D).
The set of 21 compounds were screened against a panel of
727 and 438 gene deletion mutants, representing a wide range
of biological processes in S. cerevisiae and S. pombe,
respectively, which contained 190 1:1 orthologs (Roguev
et al, 2008; Figure 3A, see Supplementary Table 3). Two highly
reproducible, independent screens were carried out in each
species (rsc¼0.72; rsp¼0.76, P-valueo10
 100; Figure 3B) and
the resulting datawasaveraged together to provide a ﬁnal data
set (see Supplementary Table 2). This data set recapitulates
many of the previously known functional interactions for the
well-studied compounds. For example, among the strongest
negative interactions (D-scores o 10) with the DNA dama-
ging agent MMS are deletions of genes belonging to the RAD52
epistasis group (RAD52, RAD55, RAD57), as well as the
mutants of the Ubc13-Mms2 ubiquitin-conjugating enzyme,
plus its interacting RING-ﬁnger gene Rad5, all known to be
important for DNA damage repair. Also, as expected, the
strongest positive (resistance) interaction with camptothecin
was its target, topoisomerase I (TOP1), whereas the strongest
negative interactions of benomyl (D-score o 15) are with
factors involved in microtubule regulation (TUB3, CIN4, CIN1,
PAC2, GIM4).
To test the accuracy of the data set, we ﬁrst checked if our
quantitative score would correctly identify known sensitive
strains. We used previously published S. cerevisiae chemical
genetic data generated in a pooled competition liquid growth
assay (Hillenmeyer et al, 2008) to deﬁne sensitive knockout
strains (those with log2 ratio 41.5) for the 12 benchmark
compounds. Additionally, compound sensitivities for MMS,
mycophenolic acid and hydroxyurea were compared with
results from previous non-competitive (i.e., not pooled in
batch culture) studies in S. cerevisiae. In all cases, sensitive
strains had much lower average D-scores than non-sensitive
strains (Supplementary information, P-value o1.7 10
 13 for
small molecules screened at approximately the same concen-
tration and P-value o0.003 for other compounds). We then
compared the D-score with the log2 ratio score deﬁned in the
study by Hillenmeyer et al (2008). For compounds appearing
in both data sets (at approximately the same concentration),
we found these two measures to be signiﬁcantly correlated
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Figure 2 Cross-species, chemogenomic screening platform. (A) Deletion
strains arrayed in 1536-format on agar plates were pin transferred onto
compound containing agar plates. These plates were then incubated and
photographed. The colony sizes were measured, the raw colony sizes
processed, and each strain was given a D-score that quantiﬁes the deviation
from an expected neutral growth model (see Materials and methods section).
(B) The expected neutral value is equal to product of the growth rate of the
deletion with the growth rate of the compound treated wild type. A negative
D-scoreindicates thatthedeletionstrain hasalowerﬁtnessthanexpected bythe
neutral combination of both perturbations. A positive one indicates that this
deletion strain grows better under this condition than expected by the neutral
model. (C) A neutral score could indicate that the compound target and the
protein corresponding to the gene deletion are in unrelated pathways (Neutral).
Anegativescorecouldindicatethatthesmallmoleculetargetsacellularpathway
that works in parallel to the pathway containing the genetic deletion (e.g.,
sensitivity). Thepositive phenotype cancome about inavariety of ways;e.g., the
query compound could target a gene that is in the same pathway as the deleted
gene (resistance I). Additionally, the drug could alter the function of a protein
(protein E in the toy example) creating a new function (function X) that is
detrimental to the cell (resistance II(i)). In the latter case, deletion of the drug-
altered protein (resistance II(ii)) would lead to resistance. (D) Chemogenomic
(D-score)proﬁlesandgenetic(S-score)proﬁlescanbecomparedviahierarchical
clustering. This type of analysis can identify small molecules with similar mode of
action (drug 1, drug 3), and can potentially pair drugs with their biological targets
(drug 2, mutant 2).
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& 2010 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2010 3Table I Compounds proﬁled in the chemogenomic screen with predicted EC50 value, screening concentration used, compound effect if known and structure
Compound
name
Molecular
weight
(g/mol)
Predicted EC50
S. cerevisiae
(mM)
Screening
concentration
S. cerevisiae (mM)
Predicted EC50
S. pombe
(mM)
Screening
concentration
S. pombe (mM)
Compound effect
(if known)
Benomyl 290.3 — 34.5; 51.5 — 34.5 Tubulin poison
Bleomycin sulfate 2841 1.7 3.2 0.33 0.64 Induces DSBs; inhibits
DNA synthesis
Caffeine 194.2 — 7700 — 1550 Promiscuous kinase inhibitor
Camptothecin 348.4 — 86 — 14; 43 Binds DNA/Top1 complex
Cycloheximide 281 — 0.18; 0.27 — 18; 53 Protein synthesis inhibitor
Fenpropimorph 303.5 — 16.5; 33 — 10; 20 Targets Erg2
Fluconazole 306.3 — 100; 200 — 100 Targets Erg11
Hydroxyurea 76.1 — 100000; 200000 — 100000 Inhibits RnR
MMS 110.1 — 1772; 3544 — 827 Methylates DNA bases
Mycophenolic acid 320.3 — 46.8; 93.8 — 46.8; 93.8 Inhibits nucleic acid synthesis
Rapamycin 914 0.2 0.003 NA 0.4 TOR pathway; binds FPR1
Tunicamycin 840 — 0.6; 1.2 — 0.2 Protein glycosylation inhibitor
NSC-109509 371 7.3 34.5 NA 34.5 Unknown
NSC-126728 502.6 5.1 1.6 0.22 0.11 Eukaryotic translation
NSC-168597 414 0.33 0.1; 0.5 0.31 0.5 Unknown
NSC-207895 279 6 16.1 1 11.5 Antitumor/DNA damaging
NSC-268879 452 0.94 4.5 2 3.6 Unknown
NSC-301460 1189 4 3 0.59 3 Immunosuppressive
NSC-305787 481 19.8 42.2 13.4 42.2 Antimalarial
NSC-620358 346 0 66.4 0 66.4 Anti-inﬂammatory/unknown
NSC-638432 407 24.9 47.2 48.2 47.2 Unknown
‘—’, compound not screened in the halo assay; ‘NA’, predicted EC50 accuracy below conﬁdence threshold.
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 16; Figure 3C). Finally, we used an
independent set deﬁned by high-conﬁdence compound–gene
interactions obtained from the STITCH (Kuhn et al,2 0 1 0 )
(http://stitch.embl.de/) database to benchmark our data set
and to compare it with previously published chemogenomic
screens of S. cerevisiae. Using the area under the receiver
operating characteristic (AROC) curve as measure of discri-
minatory power, we observed that the D-scores had a similar
discriminatory power to identify these high-conﬁdence
compound–gene interactions as previous large scale chemo-
genomic experimental studies (Supplementary information).
Together, these results argue that we have generated a robust,
reproducible data set of high quality.
Compound–module interactions show higher
cross-species conservation than compound–gene
relationships
The availability of chemogenomic data for two different yeast
species allows us to study how drug response has changed
during evolution. D-scores for 190 orthologous genes were
computed for both species and used to assess the evolutionary
conservation of compound–gene interactions (Figure 4A,
Supplementary Table 3). The low correlation between these
scores (r¼0.13), although statistically signiﬁcant (P-value
o4.4 10
 11), indicates a large degree of evolutionary
divergence of drug sensitivities among these genes. We have
previously observed a similar conservation level (r¼0.14,
P-value o 10
 170) between a large set of genetic interactions
from sets of orthologous genes in these two species (Roguev
et al, 2008).
Although individual genetic interactions are generally
poorlyconserved betweenthese fungi, conservation of genetic
interactions among genes that code for physically interacting
proteins tends to be signiﬁcantly higher (Roguev et al, 2008).
We reasoned that a similar principle could apply to
compound–gene relationships. If a complex is important for
the response to a small molecule in one yeast species then it
might also be important in the other, even if the individual
compound–gene interactions have diverged.
In order to address this question, we ﬁrst obtained a set of
previouslyreportedcompound–genefunctionalinteractionsin
S. cerevisiae from the STITCH database (Kuhn et al,2 0 1 0 ;
http://stitch.embl.de/). These interactions were then used to
deﬁne a set of high-conﬁdence compound–module interac-
tions. Modules were deﬁned as groups of proteins that are part
of the same protein complexor share gene ontology terms (see
Materials and methods section). Next, we developed the
I-score, a metric that combines the D-score between a small
molecule and a mutant with a measure of the similarity
between the genetic and chemogenomic proﬁles derived from
the same mutant and compound, respectively. The I-score was
then used to quantify both compound–gene interactions and
compound–module interactions (see Materials and methods
section; Figure 4B, top).
We evaluated the ability of our data set to predict the high-
conﬁdence functional interactions from STITCH using the
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Figure 3 Overview of chemogenomic data set. (A) A panel of 438 S. pombe deletion mutants and 727 S. cerevisiae mutants were screened. In total, 190 of these
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independent data sets were correlated in each species. The data sets were highly correlated: r¼0.72 for S. cerevisiae and 0.76 for S. pombe (P-value o10
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probability that the I-score will accurately discriminate a
known compound–gene or module interactions from a
random one. Using S. cerevisiae I-scores, an AROC value of
0.72 was observed for the discrimination of known com-
pound–geneinteractionsfromrandom(Figure4B,S.cerevisiae
to S. cerevisiae). These data also correctly identify known
module interactions over random with an AROC of 0.85. In
contrast to the above result, when S. pombe compound–gene
I-scores are used to predict S. cerevisiae compound–gene
associations, the prediction is only slightly better than random
(57%) (Figure 4B, S. pombe to S. cerevisiae), supporting the
idea that compound–gene interactions are poorly conserved.
However, S. pombe data can predict S. cerevisiae compound–
module interactions almost as well as S. cerevisiae data
(84%) (Figure 4B, S. pombe to S. cerevisiae). These results
suggest a greater conservation of compound–module interac-
tions when compared with compound–gene interactions.
Combined cross-species chemogenomic data
highlights relevant mode of action
Tolearnifusingdatafromtwodifferentspecieswouldimprove
the prediction of a small molecule’s MoA, we attempted to
predict the high-conﬁdence S. cerevisiae compound–gene and
compound–module interactions by combining information
from both species (see Materials and methods section). From
all interactions found in STITCH, we identiﬁed 15 compound–
gene and 36 compound–module interactions, for which we
had experimental data in both yeasts. In accordance with the
evolutionarypatternsobservedabove,thecombinationofdata
from both species improves compound–module association
predictions (from 85 to 94%), but does not increase the
accuracy of compound–gene predictions (Figure 4B, both yeasts
to S. cerevisiae). The improvement observed for prediction of
module interactions is statistically signiﬁcant (P-value o0.006)
and does not depend on the STITCH cutoffs used (see
Supplementary information for cutoff and statistics test). The
difference observedcould simplyresult fromthe combinationof
two imperfect predictors. To demonstrate that the improvement
is related to the data coming from two different species, we
combined our S. cerevisiae data with another larger chemoge-
nomic S. cerevisiae data set (Hillenmeyer et al, 2008). Using the
combination of both of these data sets, we observed no
signiﬁcant improvement in the ability to predict compound–
gene or compound–module interactions from STITCH
(Figure 4B, S. cerevisiae liquidþagar to S. cerevisiae).
In order to learn why combining cross-species chemoge-
nomic data might improve MoA identiﬁcation, we focused our
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and interfere with the function of microtubules. It is expected
that the effects of benomyl should mimic the effects of
knocking out microtubule components. For this reason, we
used the genetic interaction data available for these species to
search for modules that show strong genetic interactions with
microtubule factors (see Materials and methods section).
In Figure 4C, the benomyl–complex interactions (dashed
lines) were compared with the complex–complex genetic
interactions (solid lines) of microtubule-related factors for
both species. As expected, there is a highly signiﬁcant overlap
between these two networks. Of 11 complexes that genetically
interact with microtubules, 6 show signiﬁcant interactions
with benomyl. The strongest and most conserved benomyl
association identiﬁed is in fact with the primary target
(microtubules) (Davidse, 1986). In addition, we observed that
the strongest benomyl–complex associations (with the pre-
foldin complex and kinetochore components) mimic the
strong and conserved genetic interactions with microtubule
factors, whereas weaker benomyl–complex associations are
with components that have more divergent genetic interac-
tions with microtubule factors.
As noted above, the benomyl–complex interactions tend to
mirror the genetic interactions of benomyl’s primary target.
The generality of this ﬁnding was assessed by comparing the
conservation of compound–gene interactions with genetic
interactions for orthologous pairs in both species. For a given
pair of orthologs, we used the similarity of their compound–
gene score vectors and their genetic interaction scores as a
proxy for the conservation of both types of interactions. We
analyzed 89 pairs of orthologs, for which we had at least 100
genetic interaction scores in common to calculate a similarity
score. We observed that these two metrics show a modest but
signiﬁcant positive correlation (r¼0.28, N¼89, P-value¼
0.0078), suggesting that the divergence of compound–gene
interactions can be explained to some extentbythe divergence
of genetic interactions. Some of the small-molecule interac-
tions identiﬁed with chemogenomic screens are with compo-
nents that genetically interact with the primary targets. We
believe that, given that the most important functional
Drug/drug correlations, S. cerevisiae
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Figure 5 Correlation analysis of small-molecule proﬁles in S. cerevisiae and S. pombe.( A) A plot comparing pairs of small-molecule proﬁles from both ﬁssion and
budding yeasts derived from the 190 orthologs. In red are proﬁle pairs for which the compounds have a similar MoA. (B) Correlation coefﬁcients between proﬁle pairs,
comparing the proﬁle for each compound in S. cerevisiae versus the proﬁle for that same compound in S. pombe, using only the scores for the ortholog pairs. The NSC-
207895 proﬁles are most conserved between the two species. (C) Network diagram showing contributions from each species to predicted compound–module
interactions (red¼S. cerevisiae, blue¼S. pombe, purple¼equal contribution; see text for details). Line thickness is proportional to the signiﬁcance of each interaction
( log(P-value)).
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conserved across species, the availability of chemogenomic
data for multiple species allows us to identify these biologi-
cally relevant drug associations.
Finally, we wanted to test if these data from both species
could be used to make informed predictions of drug MoA in
human cells. We compiled a high-conﬁdence list of com-
pound–gene and compound–module interactions for Homo
sapiens derived from the STITCH database (see materials and
methods). We identiﬁed 56 compound–gene and 33 com-
pound–module interactions, for which we have experimental
data from either fungi by orthology. These predictions can
discriminate a known compound–gene and a compound–
complex interactions from random with an AROC of 0.64
and 0.71, respectively (Figure 4B, both yeasts to human).
These results clearly show the potential of our platform
as a model system to study drugs’ MoAs with application to
human cells.
Prediction of MoA for uncharacterized compounds
Having shown that combining chemogenomic data from both
species improves the capacity to predict known compound–
complex associations, we set out to make predictions for the
MoAofallthesmallmoleculesscreened(TableI).Weusedtwo
approaches: correlation of the small-molecule proﬁles and
high-conﬁdence predictions for compound–complex associa-
tions. First, we calculated all pairwise correlations for all
compounds in each species (Figure 5A). Correlations for
compounds that are known to have a similar effect (e.g. MMS,
hydroxyurea) are higher than average (median correlation
coefﬁcient of 0.34 versus 0.20, P-value¼0.026 with a
Kolmogorov–Smirnov test; Figure 5A, red nodes). We there-
fore reasoned that strong correlations between a well-studied
small molecule and one of unknown MoA could be used to
predict MoAs. Using this approach, we identiﬁed 17 of these
highly correlated compound pairs between an NSC compound
and one of the benchmark small molecules (see Supplemen-
tary Table 4). The most highly correlated compound proﬁles
are those of MMS/NSC-207895 and camptothecin/NSC-
207895, suggesting that this nitrobenzofuroxan is triggering
the DDR pathway (Figure 5A). Additionally, when one
correlates the S. cerevisiae and S. pombe proﬁles for the same
compound, only using D-scores for the 190 orthologs, NSC-
207895 appears as the most highly correlated pair (Figure 5B,
r¼0.48). That DNA damaging agents have the most highly
correlated proﬁles in both species could be related to the fact
that DNA damage response is a highly conserved biological
function. It should be noted that the genes used to determine
these proﬁle correlations were weighted toward DNA damage
response functions (B20%) (Figure 3A).
We used the combined data from both species to predict
compound–complexinteractions(Figure5C,seeMaterialsand
methods for details). Expected compound–complex associa-
tions are observed: e.g., benomyl has strong predicted
association scores with microtubules, the kinetochore and
the prefoldin complex, while the DNA damaging agents all
show strong interactions with the DNA repair and/or replica-
tion fork complexes. Some of these results highlight the
complexity in extrapolating MoA from chemogenomic data.
For example, we predict strong associations between tunica-
mycinwith boththeRPD3-C(L) complexandribosomes, while
it has been shown that tunicamycin inhibits the synthesis of
N-linked glycoproteins (Figure 5C). These seemingly unlikely
functional interactions are justiﬁed based on previous
literature; the compound-induced impairment of the secretory
pathways triggers the unfolded protein response, leading to a
decrease in ribosome production (Warner and Nierras, 1999)
that is regulated by the RPD3-C(L) complex (Sandmeier et al,
2002). This compound–complex network also allows us to
study previously uncharacterized compounds. For example,
the small-molecule NSC-109509 shows strong associations
with chromatin modiﬁers/remodelers COMPASS, RSC and
SET3-C (Figure 5C), suggesting that it might have an effect on
chromatin regulation. The compound NSC-207895 shows
strong functional interactions with both DNA repair and
replicationforkcomplexes,muchlikeMMSandcamptothecin,
suggesting a role for this compound in some aspect of DNA
metabolism.
Chemogenomic screen identiﬁes NSC-207895
as a DNA damaging agent
Several pieces of evidence point toward NSC-207895, a
4-nitrobenzofuroxan derivative, being a DNAdamaging agent.
Previously, compounds in this family were shown to inhibit
DNA and RNA synthesis in mammalian cells (Ghosh and
Whitehouse, 1968; Whitehouse and Ghosh, 1968). Further-
more, the proﬁles for NSC-207895 are highly correlated with
those of known DNA damaging agents, MMS and camptothe-
cin, in both yeast species (Figure 5B). Finally, Figure 5C
illustrates the similarity between compound–complex inter-
actions of those three compounds. Based on these ﬁndings we
further investigated the MoA of NSC-207895.
To determine if NSC-207895 had an effect on DNA integrity
in vivo, we measured phosphorylation of the DNA checkpoint
factor, Rad53, a hallmark of the DDR pathway. After treatment
with this uncharacterized compound, we found that the
phosphorylation levels of Rad53 had increased signiﬁcantly
(Figure 6A), suggesting that it is involved in some aspect of
DNA damage in vivo. This response is speciﬁc to NSC-207895,
as eight other randomly selected compounds do not result in a
similar activation of Rad53 (Supplementary information). We
then asked whether the compound would cause physical
damage to DNA in vitro. Damaged DNA is known to have
decreased transformation efﬁciency. We developed a plasmid-
based transformation assay for DNA damage (see Materials
and methods section) and used it to assess the effects of MMS,
hydroxyurea or NSC-207895 as DNA damaging agents. In the
case of hydroxyurea we observed little effect, consistent with
its role as a ribonucleotide reductase inhibitor (Figure 6B).
MMS,ontheotherhand,showedtheexpecteddose-dependent
decrease in transformation efﬁciency due to the known DNA-
methylating action of MMS. NSC-207895 showed no effect on
transformation efﬁciency (Figure 6B). In order to gain a better
understanding of the MoA of the NSC-207895 compound, we
tested its effect on cell cycle progression. We released
synchronized untreated cells or cells treated with MMS,
hydroxyurea or NSC-207895 and used ﬂow cytometry (FACS)
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observed that NSC-207895 caused a very signiﬁcant replica-
tion delay, one that was similar to the one observed in the
presence of MMS.
To determine if this response was evolutionarily conserved,
as suggested by the cross-species proﬁling, we monitored the
phosphorylation levels of the S. pombe ortholog of Rad53,
Cds1, and found a similar increase in its phosphorylated form
(Figure 6D). Finally, we tested the effect of this compound in
human cells and again found that the phosphorylation levels
of Chk2, the functional counterpart of budding yeast Rad53,
was increased (Figure 6E), indicating that the NSC-207895-
induced DDR is evolutionarily conserved. Whereas in budding
yeast, the Mec1 (human ATR homolog)–Rad53 (human CHK2
homolog) pathway is the major DDR pathway activated in
response to a wide range of DNAdamage and DNA replication
stress (Zhou and Elledge, 2000), there are two main DDR
pathways in mammalian cells (ATM-CHK2 and ATR-CHK1).
Moreover, ATM and ATR activation is preferentially triggered
by different genomic stresses. For example, while DNA
replication stress mainly activates the ATR kinase (CHK1),
the ATM kinase (CHK2) is activated by DNA double-strand
break repair. When we continuously tested the DDR effect of
this compound in human cells, we found that the phosphor-
ylation levels of Chk2, the functional counterpart of budding
yeast Rad53, was increased in a dose-and time-dependent
manner in human U2OS cells (Figure 6E). More strikingly, a
close examination of these phosphorylation proﬁles revealed
that NSC-207895 triggers an immediate and early activation of
ATR kinase at 1h, which was signiﬁcantly decreased at 3h. In
contrast, the ATM kinase activation is weak at 1h, but is
greater at the 3h point (Figure 6E).
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Figure 6 NSC-207895 is a DNA damaging agent. (A) We treated S. cerevisiae with known DNA damaging agents MMS and hydroxyurea, and with NSC-207895.
Rad53-phosphorylationistriggeredunderallthreeconditions,indicatingthatNSC-207895doestriggertheDDRpathwayinS.cerevisiae(B)ALEUplasmidwastreated
with DNA-methylating agent MMS, hydroxyurea or NSC-207895, and then transformed into BY4741. Decreased transformation efﬁciency compared with the control
indicates that DNA has been physically damaged, as demonstrated with MMS. NSC-207895, like hydroxyurea, does not show decreased transformation efﬁciency, and
therefore is not likely to be causing physical damage to the DNA in the plasmid environment. (C) S. cerevisiae synchronized cells were released into media containing
eithernocompound,MMS,hydroxyureaorNSC-207895,andﬂowcytometrywasusedtotrackcellcycleprogression.NSC-207895causedasigniﬁcantreplicationdelay
that was similar to the action of MMS. (D, E) To explore the conservation of compound MoA for NSC-207895, we treated S. pombe and H. sapiens U2OS cells with
MMS, hydroxyurea and NSC-207895. As in S. cerevisiae, we observed phosphorylation of cds1 in S. pombe and CHK1 and CHK2 in H. sapiens, indicating that
treatment with both control small molecules and the unknown compound all trigger the DNA damage response pathway in all three species. (D) Lane 1 is an untreated
control, while lanes 2–5 contain NSC-207895 dissolved in DMSO at ﬁnal concentration of 2.0, 4.0, 6.0, 8.0mM, respectively. For pCHK1 S317, the upper band is the
phosphorylated form, while the lower is likely a degraded species. For pCHK2 T68, the lower band is the phosphorylated form, whereas the upper band is likely pCHK2
T68 with other, as of yet, unidentiﬁed post-translational modiﬁcations.
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activates the DDR leading to a delay in cell cycle progression,
but does not covalently damage DNA in vitro. It is likely
to trigger the DDR pathway through an indirect mechanism,
such as intercalation, as it is an electron-deﬁcient, planar
aromatic compound or requires a protein target to mediate its
effect in vivo.
Discussion
In the late 90s, Alberts (1998) and Hartwell et al (1999) both
suggested that the cell’s components are organized into
functional groups or modules, and that the reductionist
approach of studying each element of a group in isolation
was limiting. They argued that cell biologists should strive to
understand how these elements work together to perform
critical cellular functions. Previous evolutionary studies have
underscored the importance of studying these functional
groups’ interactions. For example, we have observed that
positive genetic interactions between genes coding for co-
complex members are more conserved than average in S.
cerevisiae and S. pombe (Roguev et al, 2008). Furthermore, in
concordance with this ﬁnding, Jensen et al (2006) studied the
evolution of cell cycle control of gene expression and noted
that, although the timing of cell cycle regulation of different
complexes is conserved across species, the speciﬁc genes that
are regulated in each complex have signiﬁcantly diverged.
Finally, cross-species studies of phosphorylation demon-
stratedthat theaverage levelsof phosphorylation of functional
modules are conserved, although the proteins that are
phosphorylated can diverge quickly (Beltrao et al, 2009; Holt
et al, 2009; Tan et al, 2009).
The evolutionary analysis of compound interactions pre-
sented here reveals a very similar pattern, whereby the
compound–module interactions show higher conservation
than the underlying compound–gene interactions. These
different observations point to a similar and intuitive trend
that could be explained by a faster change of the relative
importance of functional module subunits relative to the
slowly evolving function of the whole module. It should be
noted that this apparent difference could, at least in part, be
due the higherstatistical powerassociated with group analysis
relative to individual scores. However, beyond the evolution-
ary interpretations, these observations have immediate
practical implications for the study of drugs’ MoAs. The
availability of similar data for a larger number of species will
further elucidate the evolutionary dynamics of these stress/
drug response functions.
Recent work has shown genetic interactions to be quite
divergent(Roguevetal,2008;Tischleretal,2008).Withthisin
mind,oneshouldbecriticalwhenapplyinggeneticdiscoveries
made in fungi to animal systems (divergence B1.4 billion
years ago; Hedges, 2002). However, fungal model systems are
very convenient for preliminary studies, and so devising a
method to add value to yeast-based predictions is highly
desirable.Toimproveyeast-basedpredictionsofdrugMoA,we
combine data from two model systems. We show that using
cross-species chemogenomic data result in a signiﬁcant
improvement in the prediction of drug targets over those
predicted from either species alone. Collecting compound–
gene interactions data in S. cerevisiae and S. pombe allowed us
to quantitatively compare drug behavior in two yeasts. This
information lead to the observation that compound NSC-
207895 behaves like known DNA damaging agents in both
species, and allowed us to accurately predict that it would also
behave as a DNA damaging agent in human cells. It should be
noted that if two drug proﬁles are highly correlated in both
species, not only do they share a MoA, but they are also
probably affecting a highly conserved biological process.
Identiﬁcation of compound pairs, which are highly correlated
in only one organism, provides information about biological
pathways that are not conserved. This information could, in
principle, be used to identify pathogen-speciﬁc drugs.
Webelievethat thestrategypresented herehasrelevancefor
the study of drug–drug interactions. Leha ´r et al (2009) have
shown that drug combinations tend to be synergistic only in
speciﬁc cellular contexts (i.e., species or cell types). The
availability of chemogenomic and genetic interaction data for
different species also opens the door for the study of drug
combinations and their evolutionary dynamics. Genetic
interaction data should allow for a rationalization of the
changes in drug synergy under different conditions observed
by Leha ´r et al (2009). This knowledge could be quite useful;
e.g., in the quest for combinatorial therapeutics, which
speciﬁcally target pathogenic microbes or diseased tissues,
leaving the host or symbiotic species unharmed.
Materials and methods
Halo assay
Compounds were taken up in DMSO at 10mM ﬁnal concentration in
384-well plates. Agar plates containing YPD or YES were seeded with
an overnight culture of either wild-type S. cerevisiae or S. pombe, and
the compounds were then pin transferred to the seeded agar plates.
The compound-treated plates were incubated and the OD of the agar
was measured using a plate reader. The presence of a ‘halo of death’
indicates an active compound, and the size of this halo can be
correlated to an inhibitory growth concentration (predicted EC50) for
each compound. The compounds were deﬁned as bioactive if theyhad
a measurable halo, indicative of growth inhibition. The cut-off was
chosen to maximize accuracy and still allow for prediction of EC50s on
the order of B200mM. The statistical analysis, cut-offs and prediction
of EC50 were performed as described previously (Woehrmann et al,
2010).
Chemogenomic screen
In order to perform a comparative analysis of compound–gene
interactions, we selected a set of 21 for chemogenomic screening
(Table I). Of these 21 compounds, 9 were a random subset of the
bioactive compounds identiﬁed in the halo assay and the remaining
were selected based on the availability of previous information for
benchmarking purposes. The strains screened were selected from the
commercially available S. cerevisiae and S. pombe haploid deletion
libraries, and were chosen to represent a wide range of biological
functions. As compound availability was a concern, we attempted to
minimize the number of strains screened while maximizing the
number of overlapping 1:1 genetic orthologs. Strains were also
selected in order to maximize complementarity with previously
collected genetic interaction data for subsequent analysis. In total,
we selected 727 S. cerevisiae strains and 438 S. pombe strains, with a
190-strain overlap of orthologs, arrayed into 1536-format. In order to
guarantee that the chemogenomic data sets for the different yeasts
are comparable, proﬁling in both species was performed with
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trations around known or predicted EC50 were tested and we kept
those that would produce strong and reproducible results. Speciﬁcally,
the ﬁnal concentrations were picked based on the following criteria:
(a) the resulting distribution of D-scores for a proﬁle had to have at
least 2  the standard deviation of the D-scores from an untreated
proﬁle, indicating that there is a signal due to the compound and (b)
the replicate proﬁles needed to correlate with each other with a
Pearson’s correlation r40.4, indicating that the data are reproducible.
Analysis of molecular properties of NCI library
compounds
Two data sets measuring the bioactivity of small molecules in yeast
were used. The ﬁrst data set comes from the halo assay described in
Figure 1A (data set A). It describes the predicted EC50 values of 2957
NCIcompoundsinbothwild-typeS.cerevisiaeandwild-typeS.pombe.
The second data set (data set B) describes the bioactivity of 87264 NCI
compoundsonS.cerevisiaestrains.Intheinitialstageoftheanticancer
drug screen that produced this data set, 87264 small molecules were
testedagainstsixdifferentstrainsofS.cerevisiae.Ofthese,12068hada
strong effect on yeast growth and 75196 did not (http://dtp.nci.nih.
gov/yacds/index.html). We downloaded the molecular structures of
each of the small molecules (ftp://ftp.ncbi.nih.gov/pubchem/) and
computed nine properties for each of them in order to assess whether
one of these properties was signiﬁcantly distinct for the small
molecules that affect growth. Small-molecule properties were com-
puted using Molinspiration’s mib tool (http://www.molinspiration.
com/). A local version of the mib tool was kindly provided by John J
Irwin of the University of California, San Francisco.
Transformation efﬁciency assay
We treated plasmid pRS315 (carrying a LEU2 marker, 449ng/ml stock
solution) with MMS (450, 112mM), hydroxyurea (200, 50mM) and
NSC-207895 (10, 2.5mM) in an equal volume of AB buffer (Stokes and
Michael, 2003) for 30min at 301C (reaction volumes B20ml). The
plasmids were then puriﬁed using a Qiagen clean-up kit; reaction
mixtures were diluted with 100ml PB buffer, agitated and ﬁltered in a
Qiagen spin column. The precipitate was washed with 0.75ml PE
buffer, spun 1 . The ﬁltrate was discarded, and then the column was
re-spun to remove residual buffer. Columns were transferred to clean,
dry 1.5-ml Eppendorf tubes. Fifty ml of EB was gently pipetted onto the
ﬁlters, and allowed to soak 1min, then spun down. The same ﬁltrate
was used to re-soak the ﬁlter, and was re-spun down. Average yields
for these reactions were B25ng/ml. These drug-treated plasmids were
transformed into S. cerevisiae (BY4741) according to the LiAc/SS
carrier DNA method (Gietz and Schiestl, 2007), and the resulting
colonies were tallied manually.
Phosphorylation of Rad53/cds1
Yeast Strains PGY1834: S. cerevisiae W303 lys2D ade2 leu2 his3 trp1
ura3 RAD53-HAHTRP1; NB2118: S. pombe h-leu1-32 ura4-D18 cds1-
2HA6his:ura4þ. All experiments were performed in rich medium:
YM-1 with 2% dextrose for S. cerevisiae and YE5S for S. pombe,a t
301C.PGY1834cellsinlogphaseweretreatedwithnoaddition,DMSO,
nocodazole (0.25, 1.25, 2.5 or 7.5mg/ml), MMS (0.05, 0.25, 0.5 or
1.5mM), HU (3.75, 18.75, 37.5 or 112.5mM) or NSC-207895 (0.5, 2.5,
5o r1 5 mM) for 2h. NB2118 cells in log phase were treated with
mediumalone,DMSO,nocodazole(0.25,2.5or25mg/ml),MMS(0.05,
0.5 or 5mM), HU (3.75, 37.5 or 375mM) or NSC-207895 (0.5, 5 or
50mM) for 4h at 301C. Cell pellets from both species were rinsed and
frozen at  801C, and then lysed in hot SDS sample buffer. Cell extracts
from S. cerevisiae were run on a 4–20% gradient polyacrylamide
gel (BioRad), whereas S. pombe cell extracts were run on 8%
polyacrylamide gels polymerized with 25mM Phos-tag Acrylamide
reagent(NARDInstituteLtd).GelscontainingPhostagwerewashedin
transfer buffer with 5mM EDTA, and then transfer buffer alone. Both
types of gels were transferred to PVDF and blotted with anti-HA
(16B12, Covance). To control for loading, the membrane from the
S. cerevisiae experiment was stained with Ponceau S, whereas the gel
from the S. pombe experiment was stained with Coommassie.
Phosphorylation of CHK1 and CHK2
U2OS cells were plated into six-well plates and cultured to 70–80% of
conﬂuency. CompoundNSC-207895was dissolvedinDMSO(1000 ),
added to each well with ﬁnal concentration at 2.0, 4.0, 6.0, 8.0mM,
respectively. Control wells were treated with equal amount of DMSO.
Cells lysates were prepared at 1.0, 3.0h treatment point by direct
addition of 1  SDS–PAGE loading buffer. About 20mg of each lysate
were separated on 4–12% SDS–PAGE gradient gels. Proteins were
transferred to PVDF membrane, followed by probing with antibodies
against Chk1 S317 (Bethyl), Chk2 T68 (Cell signaling), r-H2AX
(Millipore) and GAPDH (Santa Cruz).
Synchronization, drug treatment and FACS
For synchronized experiments, PGY1834 cells in log phase were
arrested in 10mg/ml a-factor for 3h (with an additional 10mg/ml
a-factor added after 2h), then released into medium alone, 5.3mM
MMS, 48mM NSC-207895 or 300mM hydroxyurea. Aliquots were
removed at the indicated times and ﬁxed in 70% ethanol. Samples
were subsequently treated with RNase A and proteinase K, stained
with Sytox Green, and analyzed by FACS.
High-conﬁdence set of compound–gene and
compound–module interactions derived from
the STITCH database
The STITCH database maintains a list of compound–gene association
scoresthatarederivedfromtheweightedcombinationofdifferentdata
source. These include information on direct protein physical interac-
tions and functional interactions obtained by literature mining. In
STITCH, each compound–gene association has a score ranging from 0
to 1 that relates to the strength of the functional association. We
deﬁnedhigh-conﬁdenceassociationsashavingaSTITCHscore40.65.
The results obtained do not vary with the threshold selected, and we
provide in Supplementary information the analysis performed with
cut-offs of different stringency. For each small molecule, we derived a
list of module interactions using the high-conﬁdence gene interactions
from STITCH and a set of manuallycurated complexes(Gu ¨ldeneret al,
2006; Collins et al, 2007) and Gene Ontology annotations (Ashburner
et al, 2000). We used these to search for ‘modules’ (deﬁned here as a
complex or a Gene Ontology group) with a statistically signiﬁcant
enrichment of subunits among the STITCH compound–gene interac-
tions (P-value o0.01 based on random sampling). Compound–gene
pairs deﬁned as high-conﬁdence interactions can be found in
Supplementary Table 5.
We obtained known compound–gene associations for both
S.cerevisiae and human; however, similarassociations werenot available
in S. pombe. Orthology assignment between S. pombe and S. cerevisiae
was obtained from the Fungal Orthogroups Repository (Wapinski et al,
2007); orthology assignment between the two fungi and human was
obtained from the Inparanoid database (O’Brien et al, 2005).
Combining chemogenomic data with genetic
interaction data (I-score)
To combine all available information into a single score useful for
comparisons and prediction, we developed the two-variable I-score.
The ﬁrst variable is the D-score, which is the scored interaction for a
speciﬁc small molecule/gene pair, provided by the chemogenomic
screen (see Figure 2B–D). The second variable incorporates data from
previous work in genetic–interaction screening and compares chemo-
genomic proﬁles with genetic interaction proﬁles for each small
molecule/gene pair. We have empirically observed that both tails of
the D-score distribution and the positive side of the correlation
coefﬁcient distributions are indicative of known compound–gene
interactions. We use Pearson’s correlation to quantify the similarity
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vector for all compound/gene proﬁle pairs in both S. cerevisiae and
S. pombe. In order to obtain a ﬁnal score, we have z-score normalized
both the D-score (Z-scoreD) and correlation coefﬁcients (Z-scoreCCs).
We have thus calculated a combined score as:
I-score ¼ absðZ-scoreDÞþZ-scoreCCs
I-scores were used as the measure of compound–gene association and
I-scores for both species can be found in Supplementary information
(see Supplementary Table 5).
InordertopredictknownS.cerevisiaecompound–geneassociations
based on the combined data from both fungi, the I-scores for S. pombe
are ﬁrst conferred to S. cerevisiae genes based on orthology assign-
ments and summed with the corresponding I-score in S. cerevisiae.
The same was done when predicting known human compound–gene
associations. Human compound–gene pairs were annotated with data
from both yeast species by orthology and the two scores summed.
Compound–module and module–module
association scores
We used the above-deﬁned I-score as a measure of compound–gene
association, as determined by our screening approach. In order to
predict module interactions, we calculated the average I-score of each
module (deﬁned here as a complex or a gene ontology group) and the
probability of observing a similar or higher average score based on
random sampling of an equal number of proteins (i.e., compound–
module P-value). The strength of each compound–module association
was then deﬁned as  log(P-value). We excluded all modules with less
than three members with a calculated I-score, as well very unspeciﬁc
modules composed of more than 200 members. When using the
experimental data from both fungi to predict compound–module
associations, the P-value for a module interaction was calculated
interdependently for each species and the ﬁnal score was deﬁned as:
 logðP-valueS:pombe P-valueS:cerevisiaeÞ
Compound–module interaction scores for both species are provided in
Supplementary information (see Supplementary Table 5).
Figure 4C shows complexes with signiﬁcant genetic interactions
with microtubules. For both species, we used previously available
genetic interaction data to obtain the average of the absolute S-score
between microtubules and other protein complexes. We then used
random sampling to calculate the likelihood of observing a similar of
higher value by chance. A cut-off of P-value o0.005 was used and the
line thickness was set to be proportional to  log(P-value).
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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